Skip Navigation

AIDSInfo-at-a-glance

Issue No. 52 | December 02, 2011
A Service of the U.S. Department of Health and Human ServicesView HTML version
News and Features 

Erratum Issued for the HHS Perinatal Guidelines

The September 14, 2011, edition of the Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States was recently updated:

  • Table 5 (Page 39): In the third column (Dosing Recommendations), consideration of increased lopinivir/ritionavir dosing is corrected to reflect both second and third trimester.
  • Table 5 (Page 40): The panel updated the dosing recommendations for atazanavir to include consideration of increased atazanavir/ritonavir dosing in the second and third trimester of pregnancy and to clarify dosing in pregnant women when coadministered with tenofovir, H2 antagonists, or efavirenz.
  • Special Situations - Acute HIV Infection (Page 79): The panel corrected a statement in the section to accurately represent the rate of mother-to-child transmission of HIV in New York State from 2002 to 2006, including the rates of transmission for infants born to mothers who acquired HIV during pregnancy versus for infants born to mothers who did not acquire HIV during pregnancy. It now reads: “From 2002 to 2006, 3,396 HIV-exposed neonates were born in New York State; 22% (9 of 41) infants born to mothers who acquired HIV during pregnancy became infected with HIV, compared with 1.8% of those born to mothers who did not acquire HIV during pregnancy (odds ratio [OR] 15.19, 95% confidence interval [CI], 3.98–56.30). Maternal acquisition of HIV during pregnancy was documented in only 1.3% of perinatal HIV exposures, but it was associated with 9 (13.8%) of the 65 mother-to-child transmission cases [2].
  • Table 9 (Page 139): The three-drug regimen zidovudine + nelfinavir + lamivudine for neonatal use in special circumstances has been removed from the table because the powder form of nelfinavir is no longer commercially available in the United States and hence the regimen is no longer applicable for use for infant prophylaxis.

Pediatric Guidelines Panel Accepting New Member Nominations

The Pediatric Guidelines Panel is accepting nominations for two positions on the author panel.

  • For information about the physician/clinician member position, please click here.
  • For information about the community member position, please click here.

Please submit your nominations via e-mail to Lynne M. Mofenson, M.D., Executive Secretary of the Pediatric Guidelines Panel, National Institute of Child Health and Human Development, National Institutes of Health (LM65D@nih.gov or Lynne.Mofenson@nih.hhs.gov) by Friday, December 30.

Recent News About NIH Research Studies

The NIH recently announced news about the following three NIH-sponsored research studies:

  • November 25, 2011: NIH Discontinues Tenofovir Vaginal Gel in 'VOICE' HIV Prevention Study

    “A large-scale clinical trial evaluating whether daily use of an antiretroviral-containing oral tablet or vaginal gel can prevent HIV infection in women is being modified because an interim review found that the gel, an investigational microbicide, was not effective among study participants.”

    For more information, read the NIH press release.
     
  • November 23, 2011: Scientists Determine How Antibody Recognizes Key Sugars on HIV Surface

    “HIV is coated in sugars that usually hide the virus from the immune system. Newly published research reveals how one broadly neutralizing HIV antibody actually uses part of the sugary cloak to help bind to the virus. The antibody binding site, called the V1/V2 region, represents a suitable HIV vaccine target, according to the scientists who conducted the study. In addition, their research reveals the detailed structure of the V1/V2 region, the last part of the virus surface to be visualized at the atomic level.”

    For more information, read the NIAID press release.
     
  • November 21, 2011: Cholesterol Levels Elevated in Toddlers Taking Anti-HIV Drugs

    “Toddlers receiving anti-HIV drugs have higher cholesterol levels, on average, than do their peers who do not have HIV, according to researchers at the National Institutes of Health and other institutions.”

    For more information, read the NIH press release

Home | Guidelines | Clinical Trials | Drugs | Health Topics | Education Materials | Mobile Resources & Tools
Unsubscribe | Contact Us
Left footer corner image Left footer corner image